Table 1 YKL-40 immunoreactivity and breast cancer prognostic factors

Mean/median tumor size (range)

4.0 cm/3.0 cm (0 – 20.0)

2.7 cm/2.3 cm (0 – 16.0)

<.05

Tumor differentiation*, N (%)

<.001

   • Well

1 (2)

17 (24)

   • Moderate

8 (22)

25 (35)

   • Poor

20 (54)

9 (12)

   • Unknown

8 (22)

21 (29)

ER status*, N (%)

<.01

   • Negative

21 (57)

19 (27)

   • Positive

15 (41)

52 (72)

   • Unknown/Not done

1 (2)

1 (1)

PR status*, N (%)

<.01

   • Negative

26 (71)

25 (35)

   • Positive

10 (27)

46 (64)

   • Unknown/Not done

1 (2)

1 (1)

Nodal status, N (%)

NS

   • Negative

18 (49)

32 (44)

   • Positive

19 (51)

40 (56)

Mean/median # of positive nodes (Node-positive patients only)

4.8/2.0 (1 – 22)

3.1/2.0 (1 – 17)

NS

Her2*, N (%)

NS

   • Negative

27 (73)

47 (65)

   • Positive

8 (22)

21 (29)

   • Unknown/Not done

2 (5)

4 (6)

T stage, N (%)

NS

   • T1

10 (27)

33 (46)

   • T2

17 (46)

30 (42)

   • T3

4 (11)

5 (7)

   • T4

6 (16)

4 (5)

N stage, N (%)

NS

   • N0

18 (49)

33 (46)

   • N1

11 (30)

30 (41)

   • N2

7 (19)

7 (10)

   • N3

1 (2)

2 (3)

AJCC stage, N (%)

NS

   • I

6 (16)

16 (22)

   • IIA

11 (30)

28 (39)

   • IIB

6 (16)

15 (21)

   • IIIA

7 (19)

7 (10)

   • IIIB

5 (14)

4 (6)

   • IIIC

2 (5)

1 (1)

   • IV

0 (0)

1 (1)